

Do PTK2 gene polymorphisms contribute to the inter-individual variability in muscle strength and the response to resistance training? A preliminary report

Robert M. Erskine¹, Alun G. Williams¹, David A. Jones², Claire E. Stewart² and Hans Degens²

¹*Institute for Performance Research, Department of Exercise and Sport Science, Manchester Metropolitan University, Crewe, United Kingdom;* ²*Institute for Biomedical Research into Human Movement and Health, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom.*

Author contributions: RME, AGW, DAJ, CES and HD designed the research project; RME conducted the research; RME and AGW analyzed the data; RME, AGW, DAJ, CES and HD wrote and edited the paper; RME had primary responsibility for the final content. All authors read and approved the final manuscript. The authors declared no personal or financial conflict of interest.

Address for reprint requests and all other correspondence:

R.M. Erskine, MMU Cheshire Sports Genomics Laboratory, Institute for Performance Research, Department of Exercise and Sport Science, Manchester Metropolitan University, Crewe, Cheshire, CW1 5DU, United Kingdom; Telephone: +44 (0)161 247 5087; Fax: +44 (0)161 247 6386; Email: R.M.Erskine@mmu.ac.uk

Running title: PTK2 gene variants and strength training

ABSTRACT

1 The protein tyrosine kinase-2 (PTK2) gene encodes focal adhesion kinase, a structural
2 protein involved in lateral transmission of muscle fiber force. We investigated
3 whether single nucleotide polymorphisms (SNPs) of the PTK2 gene were associated
4 with various indices of human skeletal muscle strength and the inter-individual
5 variability in the strength responses to resistance training. We determined unilateral
6 knee extension single repetition maximum (1-RM), maximum isometric voluntary
7 contraction (MVC) knee joint torque and quadriceps femoris muscle specific force
8 (maximum force per muscle physiological cross-sectional area), before and after 9-
9 weeks of knee extension resistance training in 51 untrained young men. All
10 participants were genotyped for the PTK2 intronic rs7843014 A/C and 3' UTR rs7460
11 A/T SNPs. There were no genotype associations with baseline measures or post-
12 training changes in 1-RM or MVC. Although the training-induced increase in specific
13 force was similar for all PTK2 genotypes, baseline specific force was higher in PTK2
14 rs7843014 AA and rs7460 TT homozygotes than in their respective rs7843014 C- (P
15 = 0.016) and rs7460 A-allele (P = 0.009) carriers. These associations between muscle
16 specific force and PTK2 SNPs suggest that inter-individual differences exist in the
17 way force is transmitted from the muscle fibers to the tendon. Therefore, our results
18 demonstrate for the first time the impact of genetic variation on the intrinsic strength
19 of human skeletal muscle.

20

21 **Key words:** Protein tyrosine kinase-2 (PTK2); focal adhesion kinase (FAK); gene
22 polymorphisms; costameres; lateral force transmission.

23

24 INTRODUCTION

25 Muscle force is transmitted to the tendon along the length of a muscle fiber and also
26 laterally via attachments to the surrounding matrix of connective tissue (27). It has
27 been suggested that an increase in lateral attachments after resistance training might
28 result in an enhanced muscle specific force [maximum force per physiological cross-
29 sectional area (PCSA)] (7, 12). Such attachments have been identified as intra-
30 sarcolemmal protein complexes known as “costameres” (19), which are associated
31 with the lateral transmission of muscle fiber force (6). Thus, costameres could enable
32 each muscle fiber to act as multiple force-generating units, thus increasing the specific
33 force of the whole muscle.

34

35 Mechanical tension is essential in regulating costameric protein expression (29) and
36 resistance training is known to modulate the expression of costameric proteins, such
37 as desmin (32), alpha-1-syntrophin and dystrophin (14) in humans, while focal
38 adhesion kinase (FAK) and paxillin expression and activity are increased in stretch-
39 induced hypertrophied rooster skeletal muscle (11). The integrin-associated tyrosine
40 kinase, FAK, has been shown to play a major role in costamere formation and
41 turnover (4, 20) and FAK expression is controlled at the level of the protein tyrosine
42 kinase-2 (PTK2) gene. Therefore, polymorphisms of the PTK2 gene could potentially
43 underpin the considerable inter-individual variability reported in untrained human
44 muscle specific force [ranging from 22 to 40 N·cm⁻² (8)], and in the training-induced
45 relative change in specific force, which varies between -5% and +39% (9).

46

47 As muscle strength and training responses are important from a clinical perspective,
48 e.g. the response to rehabilitation following injury, we aimed to elucidate whether

49 single nucleotide polymorphisms (SNPs) of the PTK2 gene were associated with *in*
50 *vivo* muscle specific force and functional measures of strength, both before and after
51 resistance training. We hypothesized that two PTK2 SNPs (the intronic rs7843014
52 and the 3' UTR rs7460 SNP) would be associated with QF muscle specific force and
53 with the change in specific force following training.

54

55 **MATERIALS AND METHODS**

56 *Participants*

57 Fifty-one untrained Caucasian males, aged 20.3 ± 3.1 years, height 178.1 ± 5.6 cm,
58 body mass 75.4 ± 10.6 kg, body mass index (BMI) 23.7 ± 2.6 (mean \pm SD) provided
59 written informed consent prior to their involvement in the study, which complied with
60 the Declaration of Helsinki and was approved by the local ethics committee of the
61 Manchester Metropolitan University. Study volunteers were excluded if their age was
62 outside the range of 18-39 years, they had a history of lower-limb fracture, had taken
63 part in strength training within the 12 months prior to the study, had used dietary
64 supplements or performance enhancing aids, or if they were considered to be in ill
65 health (determined by their responses to a health questionnaire). Participants were
66 familiarized with all test procedures and equipment within a 14-day period prior to the
67 baseline measurements. Phenotype data from these participants have been reported
68 previously (9).

69

70 *Habitual physical activity rating*

71 The habitual physical activity rating (PAR) of each participant was assessed by
72 questionnaire (2) immediately prior to the training period. The overall PAR was
73 scored using a scale from 1 to 5 points, where 1 was the least active, 3 was

74 intermediate and 5 was extremely active. Participants were asked to maintain their
75 PAR and habitual dietary intake over the course of the study.

76

77 *Experimental design*

78 Maximum patellar tendon force, QF muscle volume, physiological cross-sectional
79 area (PCSA) and specific force were determined in the right limb [as described in
80 Method 2 of (8)] before and after nine weeks of high-intensity unilateral knee
81 extension resistance training (10) in 51 previously untrained men. In addition, all
82 participants had blood samples isolated, which were genotyped for the PTK2 rs7460
83 A/T and rs7843014 A/C SNPs.

84

85 *Progressive resistance training*

86 The supervised resistance training protocol has been described in detail elsewhere
87 (10). Briefly, supervised knee extension training was performed unilaterally three
88 times per week for nine weeks. The maximum training load that could be lifted once
89 only (1-RM) throughout the full range of knee extension (110° to 20° of knee flexion;
90 0° = full knee extension) was assessed at the beginning of the training program and
91 re-evaluated at the start of each week on a standard knee extension machine
92 (Technogym, Gambettola, Italy). The training intensity was set in relation to the 1-
93 RM and was therefore progressively increased throughout the nine weeks of training.
94 Each session comprised a warm-up set of 10 knee extension repetitions at 40% of the
95 revised 1-RM, followed by four sets (2 min rest between each) of 10 repetitions at
96 80% 1-RM. Compliance with the training protocol was 100%, with each participant
97 completing all 27 training sessions.

98

99 *Maximum patellar tendon force*

100 The method used to assess maximum patellar tendon force has been explained in
101 detail elsewhere (8). In summary, participants performed isometric knee extension
102 maximal voluntary contractions (MVCs) on a dynamometer (Cybex Norm, Cybex
103 International, Ronkonkoma, NY) at optimum knee joint angle, which ranged from 70-
104 90° knee flexion. Participants were seated with a hip angle of 85° (supine = 180°) and
105 were fixed with inextensible straps to the strength-testing chair. Co-contraction torque
106 of the antagonist muscles during knee extension MVC was calculated by comparing
107 electromyographic activity of the biceps femoris muscle during maximal isometric
108 knee extension and maximal isometric knee flexion (21). Two bipolar silver chloride
109 surface electrodes (Neuroline, Medicotest, Rugmarken, Denmark) were placed 20 mm
110 apart along the sagittal axis over the muscle belly (the location was recorded on an
111 acetate for further tests) and one reference electrode was positioned over the lateral
112 tibial condyle. The root mean square of the raw EMG signal was calculated over one
113 second around the peak torque during each maximum voluntary isometric knee
114 extension and flexion at optimum joint angle and the torque produced by the
115 hamstrings during knee extension was estimated assuming a linear relationship
116 between torque and EMG activity (21). The estimated antagonist torque obtained at
117 the optimum knee extension joint angle was used to calculate the maximum overall
118 knee extension torque. Voluntary QF muscle activation was assessed using the
119 interpolated twitch technique (25), whereby the participant received a supramaximal
120 twitch (Digitimer stimulator model DS7, Welwyn Garden City, UK) via two 7.5 cm x
121 12.5 cm self-adhesive electrodes (Versastim, Conmed, New York, NY) placed distally
122 (anode) and proximally (cathode) over the QF muscle, once before MVC (control
123 twitch) and once during MVC. True maximum torque (TMT) was calculated as:

124
$$\text{TMT} = \text{MVC}(\text{C}) \cdot (1-t/\text{T})^{-1}$$

125 where t is the amplitude of the superimposed twitch, T is the value of the twitch
126 before the MVC and $\text{MVC}(\text{C})$ is MVC corrected for antagonist muscle co-activation.

127 The percentage of voluntary muscle activation was given by:

128
$$100 \cdot (1-t/\text{T})$$

129 The patellar tendon moment arm (d_{PT}) was determined using a 0.2-T magnetic
130 resonance imaging (MRI) scanner (G-Scan, Esaote Biomedica, Genoa, Italy), as
131 previously described (30). Sagittal and coronal-plane knee scans were acquired using
132 a Turbo 3D T1-weighted sequence with the following scanning parameters: time of
133 repetition 40 ms; time to echo 16 ms; matrix 256 x 256; field of view 180 mm x 180
134 mm; slice thickness 3.4 mm; interslice gap 0 mm. The knee was scanned at rest with
135 the participant in the supine position and the knee fully extended. Coronal scans were
136 used to identify the appropriate sagittal scans, which were used to locate the centre of
137 rotation (COR), i.e. the midpoint of the shortest distance between the two femoral
138 condyles and the tibial plateau, and d_{PT} was defined as the perpendicular distance
139 between the COR and the axis of the patellar tendon (30). Previously reported ratios
140 of d_{PT} at full extension (0 degrees knee flexion) to d_{PT} at of 70, 80 and 90 degrees
141 knee flexion (3) were used to calculate d_{PT} at optimum knee joint angle in this study.
142 Subsequently, maximum force resolved at the patellar tendon (F_t) was calculated as:

143
$$F_t = \text{TMT} / d_{\text{PT}}$$

144

145 *Muscle physiological cross-sectional area (PCSA)*

146 QF muscle PCSA was determined from a method that has been described in detail
147 previously [Method 2 of (8)]. In brief, ultrasonography (MyLab25, Esaote Biomedica,
148 Genoa, Italy) was used to identify femur length (the distance from the proximal origin

149 of the VL muscle to the tibiofemoral contact point). ACSA of each component QF
150 muscle was assessed from transverse MRI scans acquired at 40% femur length from
151 the distal end. QF muscle volume (V_m) was calculated by adapting a previously
152 described method (15) that incorporated femur length, the ACSA of each constituent
153 QF muscle and a series of regression equations. VL muscle fascicle length (L_f) and
154 pennation angle (θ_p) were measured during knee extension MVC at optimum knee
155 angle using ultrasonography at 50% of the muscle length along the mid-sagittal plane.
156 Dividing V_m by VL muscle L_f provided QF PCSA [VL L_f has been shown to be
157 representative of the L_f for the whole QF muscle group (8)].

158

159 *In vivo muscle specific force*

160 QF muscle force is reduced when resolved along the patellar tendon according to the
161 θ_p . Therefore, QF PCSA was multiplied by the cosine of VL θ_p , which provided the
162 reduced QF PCSA. Consequently, specific force was determined by dividing F_t by the
163 reduced QF PCSA (8).

164

165 *Blood sampling*

166 A 10-mL blood sample was drawn into 10-mL EDTA tubes (BD Vacutainer Systems,
167 Plymouth, UK) from a superficial forearm vein. The whole blood was aliquotted into
168 2-mL tubes (Eppendorf AG, Hamburg, Germany) and stored at -80°C until
169 subsequent analysis.

170

171 *DNA extraction and determination of PTK2 genotype*

172 Automated DNA extraction was performed using a QIAcube (Qiagen, Crawley, UK)
173 in association with the QIAamp DNA Blood Kit (Qiagen, Crawley, UK), and
174 following the QIAamp spin protocol for DNA purification from whole blood.

175

176 Real-time polymerase chain reaction (PCR) was performed to determine the genotype
177 of the PTK2 polymorphisms in each participant. Reactions were carried out on 96-
178 well microtiter plates. Each 10- μ L reaction volume contained: 5- μ L Genotyping
179 Master Mix (Applied Biosystems, Foster City, CA), 4.3- μ L nuclease-free H₂O
180 (Qiagen, Crawley, UK), 0.5- μ L genotyping assay mix (Applied Biosystems, Foster
181 City, CA), plus 0.2- μ L sample DNA at a concentration of \sim 30 ng- μ L⁻¹ and an
182 A260/A280 ratio of 1.7–1.9. TaqMan rs7843014 and rs7460 SNP genotyping assay
183 mixes were used, and each mix included the appropriate TaqMan primers and probes.

184

185 For control wells, 0.2- μ L nuclease-free H₂O replaced the DNA template. Following
186 sealing (Microseal 'B' adhesive seal, BioRad Laboratories, Hercules, CA) and
187 centrifugation at 8,000 RPM for 1 min, DNA amplification (Chromo4 Real-Time
188 PCR Detection System, BioRad Laboratories, Hercules, CA) was performed using the
189 following PCR protocol: denaturation at 95°C for 10 min, followed by 40 cycles of
190 incubation at 92°C for 15 s then annealing and extension at 60°C for 1 min. PTK2
191 genotypes were ultimately determined using Opticon Monitor 3.1 software (BioRad
192 Laboratories, Hercules, CA). All samples were analyzed in duplicate and in all cases
193 there was 100% agreement between genotype for samples from the same participant.

194

195 We performed the genotyping in accordance with published genotyping and quality
196 control recommendations (5). These included describing genotyping assays and

197 protocols in detail, producing an overview of sample ID and well number prior to
198 genotyping, including external control samples, incorporating internal controls by
199 genotyping samples in duplicate (from the same DNA collection), comparing current
200 genotype frequencies with previously published frequencies in a similar population
201 and evaluating the level of agreement with the Hardy-Weinberg principle. The extent
202 of linkage disequilibrium (LD) between the two PTK2 SNPs was investigated by
203 using freely available software (<http://linkage.rockefeller.edu/ott/eh.htm>) to estimate
204 the haplotype frequencies. The difference between the expected and observed
205 haplotype frequencies was then calculated and reported as D' and R^2 .

206

207 *Statistical analysis*

208 Genotype frequencies for each PTK2 SNP were tested for compliance with the Hardy-
209 Weinberg principle using χ^2 tests. Repeated measures ANOVAs [within subjects
210 factor: time (pre- and post-training); between subjects factor: group (3 genotype
211 levels)] were used to detect associations between each PTK2 SNP and 1-RM, MVC
212 knee joint torque and QF muscle specific force before and after training. If a tendency
213 was observed between group or for a group x time interaction, i.e. $0.05 < P < 0.10$, the
214 two genotypes with similar means were pooled and the ANOVA re-run with post-hoc
215 independent t -tests. The individual and combined contributions of the PTK2 SNPs
216 towards the inter-individual variance in muscle specific force were determined using a
217 multiple linear regression model that included both SNPs. Significance was accepted
218 when $P < 0.05$ and statistical tests were performed using SPSS v19. All data are
219 presented as mean \pm standard deviation (SD) unless otherwise stated.

220

221 **RESULTS**

222 *PTK2 genotypes*

223 The genotype frequencies for the PTK2 rs7843014 (AA = 37.3%; AC = 41.2%; CC =
224 21.6%) and rs7460 (AA = 25.5%; AT = 41.2%; TT = 33.3%) polymorphisms were all
225 in Hardy-Weinberg equilibrium ($P \geq 0.473$). Further, the PTK2 rs7843014 A/C and
226 rs7460 A/T allele frequencies were similar to those reported elsewhere for Caucasian
227 populations (31).

228

229 *Habitual physical activity rating*

230 The habitual physical activity rating (PAR) for the total cohort was 2.7 ± 0.3 and can
231 be described as slightly less than “intermediate” (2). Furthermore, none of the
232 physical characteristics (age, stature, body mass, BMI) or PAR differed between
233 genotype regarding either polymorphism: PTK2 rs7843014 A/C ($P \geq 0.135$); rs7460
234 A/T ($P \geq 0.102$).

235

236 *Single repetition maximum (1-RM)*

237 Baseline 1-RM (54.3 ± 11.0 kg for the whole cohort) did not differ between genotype
238 for both the rs7843014 (ANOVA, genotype $P = 0.659$; Table 1) and the rs7460
239 (ANOVA, genotype $P = 0.740$; Table 1) SNPs. Similarly, the % change in 1-RM
240 ($+66.8 \pm 30.2\%$ for the entire group) did not differ between genotype for either SNP
241 (rs7843014: ANOVA, time x genotype $P = 0.306$; Table 1; rs7460: ANOVA, time x
242 genotype $P = 0.839$; Table 2).

243

244 *Table 1 near here.*

245

246 *Maximum isometric voluntary contraction (MVC) knee joint torque*

247 Before training, MVC torque (248 ± 52 N·m for the entire cohort) did not differ
248 between genotype regarding either the rs7843014 (ANOVA, genotype $P = 0.826$;
249 Table 1) or the rs7460 (ANOVA, genotype $P = 0.697$; Table 2) SNPs. In addition, the
250 % change in MVC torque ($26.1 \pm 10.7\%$ for the whole group) did not differ between
251 genotype for either SNP (rs7843014: ANOVA, time x genotype $P = 0.642$; Table 1;
252 rs7460: ANOVA, time x genotype $P = 0.553$; Table 2).

253

254 *Table 2 near here.*

255

256 *Muscle physiological cross-sectional area (PCSA)*

257 Prior to training, QF muscle PCSA for the total cohort was 239 ± 40 cm², and there
258 was no association with either SNP (ANOVA, genotype $P \geq 0.314$). Nine weeks of
259 resistance training led to a $5.8 \pm 4.5\%$ increase in muscle PCSA (ANOVA, time $P <$
260 0.0005), which was independent of PTK2 genotype (ANOVA, time x genotype $P \geq$
261 0.963).

262

263 *Muscle specific force*

264 Regarding untrained muscle specific force (25.5 ± 5.2 N·cm⁻¹ for the entire group),
265 there were non-significant tendencies for PTK2 rs7843014 AA homozygotes to
266 produce higher muscle specific force than their AC and CC counterparts (ANOVA
267 genotype $P = 0.078$; Table 1), and the muscles of PTK2 rs7460 TT homozygotes to
268 have higher specific force than AA and AT genotypes (ANOVA, genotype $P = 0.058$;
269 Table 2). When the PTK2 rs7843014 AC and CC genotypes were pooled, the QF
270 muscles of individuals homozygous for the A-allele expressed higher specific force
271 than carriers of the C-allele before training (ANOVA, genotype $P = 0.023$; Table 1; *t-*

272 test $P = 0.016$; Fig. 1). Similarly, when the PTK2 rs7460 AA and AT genotypes were
273 combined, QF muscle specific force was found to be higher in TT homozygotes than
274 in A-allele carriers before training (ANOVA, genotype $P = 0.017$; Table 2; t -test $P =$
275 0.009 ; Fig. 1). However, there was no significant interaction between training and
276 PTK2 genotype concerning QF muscle specific force and both the rs7843014
277 (ANOVA, time x genotype $P = 0.601$; time $P < 0.0005$; Table 1) and rs7460
278 (ANOVA, time x genotype $P = 0.461$; time $P < 0.0005$; Table 2) PTK2 SNPs,
279 implying that specific force increased similarly among all three genotypes of both
280 SNPs ($16.4 \pm 11.2\%$ for the whole cohort).

281

282 *Fig. 1 near here*

283

284 As both SNPs of the PTK2 gene were associated with QF muscle specific force, and a
285 large proportion of participants (33%) possessed both ‘preferential’ genotypes, it was
286 further investigated whether or not the loci and PTK2 alleles were independent from
287 each other. The estimated haplotype frequencies are presented in Table 3, and the
288 deviation of the observed haplotype frequency from the expected frequency was
289 calculated and defined as the linkage disequilibrium (LD). The LD for the two PTK2
290 polymorphisms was $D' = 0.905$ and $R^2 = 0.700$, which suggests that the two
291 polymorphisms are in LD and are not completely independent from one another.

292

293 *Table 3 near here.*

294

295 Both PTK2 SNPs were associated with untrained muscle specific force, therefore the
296 contribution of each SNP to the inter-individual variance in the respective muscle

297 phenotype was investigated. On an individual basis, PTK2 rs7843014 genotype
298 correlated with baseline muscle specific force ($R^2 = 0.091$; $P = 0.031$), suggesting that
299 genotype for this SNP alone contributed to ~9% of the inter-individual variability in
300 muscle specific force in the untrained state. PTK2 rs7460 genotype also correlated
301 with baseline muscle specific force ($R^2 = 0.102$; $P = 0.022$), thus implying that
302 genotype for this SNP explained ~10% of the inter-individual variability in untrained
303 muscle specific force. Combining the two PTK2 SNPs in a multiple regression model
304 led to a tendency towards a correlation with untrained muscle specific force ($R^2 =$
305 0.105 ; $P = 0.071$). Although this correlation did not reach statistical significance, it is
306 interesting to note that the coefficient of determination was similar to that of the
307 individual PTK2 SNPs, which is probably due to the relatively high LD between the
308 two SNPs.

309

310 **DISCUSSION**

311 We investigated whether associations existed between polymorphisms of the PTK2
312 gene and human skeletal muscle strength phenotypes before and after resistance
313 training. The two PTK2 gene polymorphisms were significantly associated with the
314 inter-individual variability in muscle specific force but did not contribute to the
315 observed inter-individual variation in the training response. Thus, our results highlight
316 a novel association between sequence variations in the PTK2 gene and the intrinsic
317 force generating capacity of human skeletal muscle, possibly via influences on lateral
318 force transmission. It should be noted, however, that the data presented in this study
319 are preliminary in that the sample size is a limitation. Thus, future studies should
320 attempt to replicate our findings using larger cohorts from the same and other ethnic

321 populations, which would increase both the power of the study and the confidence in
322 our results.

323

324 The genotype frequencies for the PTK2 rs7843014 (AA = 37%; AC = 41%; CC =
325 22%) and rs7460 (AA = 26%; AT = 41%; TT = 33%) SNPs observed in our study
326 were comparable to those reported previously for Caucasian populations (31).

327 Baseline values for our entire cohort were similar to those reported elsewhere for this
328 population concerning 1-RM lifting strength (13), isometric MVC knee joint torque
329 (18), QF muscle PCSA (16) and specific force (16). Our observed 67% increase in 1-
330 RM for the whole cohort was higher than some (22), but less than other (23, 24)
331 reports of 1-RM strength gains following a similar period of knee extensor strength
332 training. The 26% increase in isometric knee extensor MVC strength was less than
333 some (26), but greater than other (1, 17) previously reported gains in isometric
334 strength following a similar duration of knee extensor training. Regarding muscle
335 hypertrophy, our observed 6% increase in QF muscle PCSA was comparable to
336 previous reports of QF muscle size gains following resistance training of similar type
337 and duration (1, 17). The 16% increase in muscle specific force was also comparable
338 to that reported elsewhere following resistance training of the QF muscle, although in
339 older individuals (21).

340

341 Focal adhesion kinase (FAK) plays an integral role in the costamere protein complex
342 (4, 20) that is involved in the lateral transmission of force (6). As FAK is encoded by
343 the PTK2 gene, we hypothesized that polymorphisms of this gene would explain part
344 of the inter-individual variability in QF muscle specific force between untrained
345 young men. We determined that individuals homozygous for the rs7843014 A-allele

346 had a higher muscle specific force than carriers of the C-allele, while QF muscle
347 specific force was greater in rs7460 TT homozygotes compared to their A-allele
348 counterparts.

349

350 Of the 19 participants who possessed one or both of the preferential PTK2 genotypes
351 (rs7843014 AA or rs7460 TT), 17 people possessed both genotypes. Individually and
352 combined, these two SNPs explained ~10% of the inter-individual variability in
353 muscle specific force in the untrained state. Thus, these findings suggest that the two
354 SNPs are not independently associated with *in vivo* muscle specific force but that they
355 are in linkage disequilibrium, which is supported by a D' value of 0.91 and R^2 value
356 of 0.70. This opens up several theoretical possibilities: 1) only one locus is
357 functionally important regarding muscle specific force; 2) the SNPs become
358 functional only when they occur together; 3) neither SNP influences muscle specific
359 force but both are in linkage disequilibrium with the true functional variant that was
360 not genotyped. In any case, neither of the PTK2 SNPs investigated in our study are of
361 a kind likely to influence the amino acid sequence of the protein product. However, an
362 alteration in DNA sequence in the 3'UTR region of a gene (e.g. the PTK2 rs7460 A/T
363 polymorphism) has the potential to alter the level, location or timing of gene
364 expression, while intronic genomic variants (e.g. the PTK2 rs7843014 A/C
365 polymorphism) generally have the potential to influence gene expression and mRNA
366 stability (28). Therefore, a potential influence of PTK2 gene polymorphisms on the
367 concentration and time course of FAK expression warrants future investigation.

368

369 We hypothesized that PTK2 genotype would influence muscle specific force, leading
370 to associations with functional measures of strength, such as maximum dynamic

371 lifting strength (1-RM) and isometric MVC knee joint torque. While we did find
372 PTK2 genotype associations with untrained QF muscle specific force, we observed no
373 association with baseline 1-RM or MVC torque. Although the intrinsic strength of the
374 muscle undoubtedly contributes to both 1-RM and MVC torque, extrinsic factors such
375 as neural drive, moment arm length, muscle size and architecture are also known to
376 influence such strength measures independent of specific force (8), thus potentially
377 masking any genotype associations with 1-RM and MVC torque.

378

379 Mechanical tension is known to regulate costameric protein expression (29) and
380 resistance training increases the expression of costameric proteins, such as desmin
381 (32), alpha-1-syntrophin and dystrophin (14) in humans, and FAK in hypertrophied
382 rooster skeletal muscle (11). Therefore, we hypothesized that PTK2 genotype would
383 influence the previously reported inter-individual variability in the training-induced
384 change in muscle specific force, 1-RM and MVC torque (9), possibly through a
385 genotype-dependent change in costameric density with loading. However, we found
386 no association between either PTK2 SNP and the relative changes in muscle specific
387 force, 1-RM or MVC torque following 9 weeks of resistance training. If any inherent
388 difference between PTK2 genotype in the level of FAK protein expression is not
389 preferentially enhanced with loading, muscle specific force will increase similarly
390 between genotype. The higher muscle specific force at baseline might then be
391 attributable to a greater muscle costameric density, which could be realized by 1) a
392 higher number of costameres per muscle fiber perimeter and/or 2) a larger number of
393 smaller fibers per muscle with a higher fiber perimeter to area ratio. Preliminary
394 (unpublished) histological data from our laboratory suggest that people with the
395 ‘preferential’ PTK2 AA genotype do have smaller muscle fiber CSAs than their ‘non-

396 preferential' genotype counterparts, and together with a non-association between
397 PTK2 genotype and muscle PCSA reported here, this would support the second
398 hypothesis. In this case, a larger loading-induced increase in FAK expression in
399 people with the higher baseline specific force, i.e. people with the 'preferential' PTK2
400 genotypes, might be offset by a relatively greater loading-induced increase in the
401 perimeter of large compared to small fibers (assuming a similar relative increase in
402 fiber CSA). This would lead to a similar increase in total muscle costameric density
403 between genotype, which in turn would lead to comparable training-induced increases
404 in muscle specific force.

405

406 *Summary and conclusions*

407 The inter-individual variability in QF muscle specific force can be partly explained by
408 polymorphisms of the PTK2 gene that encodes FAK, a structural protein involved in
409 the lateral transmission of muscle fiber force. Future experiments should investigate
410 potential associations between PTK2 genotype and FAK expression in skeletal
411 muscle. These results highlight the impact of genetic variation on the intrinsic
412 strength of human skeletal muscle.

REFERENCES

1. **Aagaard P, Andersen JL, Dyhre-Poulsen P, Leffers AM, Wagner A, Magnusson SP, Halkjaer-Kristensen J, and Simonsen EB.** A mechanism for increased contractile strength of human pennate muscle in response to strength training: changes in muscle architecture. *J Physiol* 534: 613-623, 2001.
2. **Baecke JA, Burema J, and Frijters JE.** A short questionnaire for the measurement of habitual physical activity in epidemiological studies. *Am J Clin Nutr* 36: 936-942, 1982.
3. **Baltzopoulos V.** A videofluoroscopy method for optical distortion correction and measurement of knee-joint kinematics. *Clin Biomech (Bristol, Avon)* 10: 85-92, 1995.
4. **Cary LA, and Guan JL.** Focal adhesion kinase in integrin-mediated signaling. *Front Biosci* 4: D102-113, 1999.
5. **Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, Brooks LD, Cardon LR, Daly M, Donnelly P, Fraumeni JF, Jr., Freimer NB, Gerhard DS, Gunter C, Guttmacher AE, Guyer MS, Harris EL, Hoh J, Hoover R, Kong CA, Merikangas KR, Morton CC, Palmer LJ, Phimister EG, Rice JP, Roberts J, Rotimi C, Tucker MA, Vogan KJ, Wacholder S, Wijsman EM, Winn DM, and Collins FS.** Replicating genotype-phenotype associations. *Nature* 447: 655-660, 2007.
6. **Danowski BA, Imanaka-Yoshida K, Sanger JM, and Sanger JW.** Costameres are sites of force transmission to the substratum in adult rat cardiomyocytes. *J Cell Biol* 118: 1411-1420, 1992.
7. **Erskine RM, Jones DA, Maffulli N, Williams AG, Stewart CE, and Degens H.** What causes in vivo muscle specific tension to increase following resistance training? *Exp Physiol* 96: 145-155, 2011.
8. **Erskine RM, Jones DA, Maganaris CN, and Degens H.** In vivo specific tension of the human quadriceps femoris muscle. *Eur J Appl Physiol* 106: 827-838, 2009.
9. **Erskine RM, Jones DA, Williams AG, Stewart CE, and Degens H.** Inter-individual variability in the adaptation of human muscle specific tension to progressive resistance training. *Eur J Appl Physiol* 110: 1117-1125, 2010.
10. **Erskine RM, Jones DA, Williams AG, Stewart CE, and Degens H.** Resistance training increases in vivo quadriceps femoris muscle specific tension in young men. *Acta Physiol (Oxf)* 199: 83-89, 2010.
11. **Fluck M, Carson JA, Gordon SE, Ziemiecki A, and Booth FW.** Focal adhesion proteins FAK and paxillin increase in hypertrophied skeletal muscle. *Am J Physiol* 277: C152-162, 1999.

12. **Jones DA, Rutherford OM, and Parker DF.** Physiological changes in skeletal muscle as a result of strength training. *Q J Exp Physiol* 74: 233-256, 1989.
13. **Kokkonen J, Nelson AG, Eldredge C, and Winchester JB.** Chronic static stretching improves exercise performance. *Med Sci Sports Exerc* 39: 1825-1831, 2007.
14. **Kosek DJ, and Bamman MM.** Modulation of the dystrophin-associated protein complex in response to resistance training in young and older men. *J Appl Physiol* 104: 1476-1484, 2008.
15. **Morse CI, Degens H, and Jones DA.** The validity of estimating quadriceps volume from single MRI cross-sections in young men. *Eur J Appl Physiol* 100: 267-274, 2007.
16. **Narici MV, Landoni L, and Minetti AE.** Assessment of human knee extensor muscles stress from in vivo physiological cross-sectional area and strength measurements. *Eur J Appl Physiol Occup Physiol* 65: 438-444, 1992.
17. **Narici MV, Roi GS, Landoni L, Minetti AE, and Cerretelli P.** Changes in force, cross-sectional area and neural activation during strength training and detraining of the human quadriceps. *Eur J Appl Physiol Occup Physiol* 59: 310-319, 1989.
18. **O'Brien TD, Reeves ND, Baltzopoulos V, Jones DA, and Maganaris CN.** In vivo measurements of muscle specific tension in adults and children. *Exp Physiol* 95: 202-210, 2010.
19. **Pardo JV, Siliciano JD, and Craig SW.** Vinculin is a component of an extensive network of myofibril-sarcolemma attachment regions in cardiac muscle fibers. *J Cell Biol* 97: 1081-1088, 1983.
20. **Quach NL, and Rando TA.** Focal adhesion kinase is essential for costamerogenesis in cultured skeletal muscle cells. *Dev Biol* 293: 38-52, 2006.
21. **Reeves ND, Narici MV, and Maganaris CN.** Effect of resistance training on skeletal muscle-specific force in elderly humans. *J Appl Physiol* 96: 885-892, 2004.
22. **Riechman SE, Balasekaran G, Roth SM, and Ferrell RE.** Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. *J Appl Physiol* 97: 2214-2219, 2004.
23. **Rutherford OM, Greig CA, Sargeant AJ, and Jones DA.** Strength training and power output: transference effects in the human quadriceps muscle. *J Sports Sci* 4: 101-107, 1986.
24. **Rutherford OM, and Jones DA.** The role of learning and coordination in strength training. *Eur J Appl Physiol Occup Physiol* 55: 100-105, 1986.
25. **Rutherford OM, Jones DA, and Newham DJ.** Clinical and experimental application of the percutaneous twitch superimposition technique for the study of human muscle activation. *J Neurol Neurosurg Psychiatry* 49: 1288-1291, 1986.

26. **Seynnes OR, de Boer M, and Narici MV.** Early skeletal muscle hypertrophy and architectural changes in response to high-intensity resistance training. *J Appl Physiol* 102: 368-373, 2007.
27. **Street SF.** Lateral transmission of tension in frog myofibers: a myofibrillar network and transverse cytoskeletal connections are possible transmitters. *J Cell Physiol* 114: 346-364, 1983.
28. **Tabor HK, Risch NJ, and Myers RM.** Candidate-gene approaches for studying complex genetic traits: practical considerations. *Nat Rev Genet* 3: 391-397, 2002.
29. **Tidball JG, Spencer MJ, Wehling M, and Lavergne E.** Nitric-oxide synthase is a mechanical signal transducer that modulates talin and vinculin expression. *J Biol Chem* 274: 33155-33160, 1999.
30. **Tsaopoulos DE, Baltzopoulos V, and Maganaris CN.** Human patellar tendon moment arm length: measurement considerations and clinical implications for joint loading assessment. *Clin Biomech (Bristol, Avon)* 21: 657-667, 2006.
31. **Voight BF, Kudaravalli S, Wen X, and Pritchard JK.** A map of recent positive selection in the human genome. *PLoS Biol* 4: e72, 2006.
32. **Woolstenhulme MT, Conlee RK, Drummond MJ, Stites AW, and Parcell AC.** Temporal response of desmin and dystrophin proteins to progressive resistance exercise in human skeletal muscle. *J Appl Physiol* 100: 1876-1882, 2006.

Tables

Table 1. Baseline values and training-induced changes in muscle strength variables in participants according to protein tyrosine kinase-2 (PTK2) rs7843014 genotype; repeated measures ANOVA P -values are presented for genotype (Pre) and training response (Δ) comparisons for the 3 genotypes (P_1), and AA vs. AC + CC (P_2).

Strength variable	PTK2 rs7843014 genotype			P_1	AC + CC ($n = 32$)	P_2
	AA ($n = 19$)	AC ($n = 21$)	CC ($n = 11$)			
Pre 1-RM (kg)	55.0 ± 13.2	53.8 ± 9.7	54.1 ± 10.9	0.659	53.9 ± 10.0	0.979
Δ 1-RM (%)	64.4 ± 31.9	64.6 ± 28.2	77.0 ± 31.9	0.306	69.0 ± 29.6	0.511
Pre MVC (N·m)	252 ± 58	245 ± 52	245 ± 42	0.826	245 ± 48	0.546
Δ MVC (%)	26.7 ± 8.0	25.4 ± 12.5	26.2 ± 11.9	0.642	25.7 ± 12.1	0.443
Pre SF (N·cm ⁻²)	27.7 ± 6.4	24.2 ± 3.7	23.9 ± 4.4	0.078	24.1 ± 3.9*	0.023
Δ SF (%)	16.2 ± 10.5	14.7 ± 11.3	20.0 ± 12.4	0.601	16.5 ± 11.8	0.797

AA homozygote; AC heterozygote; CC homozygote; Pre before training; Δ relative change after training; 1-RM single repetition maximum; MVC maximum isometric voluntary contraction knee joint torque; SF quadriceps femoris muscle specific force; *significantly different from AA genotype (post-hoc independent t -test: $P = 0.016$).

Table 2. Baseline values and training-induced changes in muscle strength variables in participants according to protein tyrosine kinase-2 (PTK2) rs7460 genotype; repeated measures ANOVA *P*-values are presented for genotype (Pre) and training response (Δ) comparisons for the 3 genotypes (P_1), and TT vs. AT + AA (P_2).

Strength variable	PTK2 rs7460 genotype			P_1	AA + AT ($n = 34$)	P_2
	AA ($n = 13$)	AT ($n = 21$)	TT ($n = 17$)			
Pre 1-RM (kg)	54.6 \pm 9.7	53.0 \pm 10.4	55.7 \pm 13.4	0.740	53.6 \pm 10.0	0.706
Δ 1-RM (%)	69.3 \pm 32.3	67.7 \pm 27.3	65.2 \pm 34.0	0.839	68.4 \pm 28.9	0.650
Pre MVC (N·m)	243 \pm 47	244 \pm 51	256 \pm 58	0.697	244 \pm 49	0.402
Δ MVC (%)	28.7 \pm 11.7	25.1 \pm 12.6	25.2 \pm 7.0	0.553	26.5 \pm 12.2	0.706
Pre SF (N·cm ⁻²)	24.0 \pm 4.0	24.2 \pm 3.6	28.1 \pm 6.6	0.058	24.1 \pm 3.7**	0.017
Δ SF (%)	20.8 \pm 11.9	14.4 \pm 11.6	15.5 \pm 9.8	0.461	16.9 \pm 12.0	0.975

AA homozygote; *AT* heterozygote; *TT* homozygote; *Pre* before training; Δ relative change after training; *1-RM* single repetition maximum; *MVC* maximum isometric voluntary contraction knee joint torque; *SF* quadriceps femoris muscle specific force; **significantly different from TT genotype (post-hoc independent *t*-test: $P = 0.009$).

Table 3. Estimates of haplotype frequencies regarding the protein tyrosine kinase-2 (PTK2) rs7843014 (A/C) and rs7460 (A/T) polymorphisms.

Allele at locus 1 (rs7843014 A/C)	Allele at locus 2 (rs7460 A/T)	Haplotype frequency
A	T	0.519
A	A	0.060
C	T	0.021
C	A	0.401

Figure legend

Fig. 1. Baseline quadriceps femoris muscle specific force according to non-preferential (white bars) and preferential (black bars) genotypes of the protein tyrosine kinase-2 (PTK2) rs7843014 (preferential genotype: AA) and rs7460 (preferential genotype: TT); * $P = 0.016$ significantly different from pooled PTK2 rs7843014 AC + CC genotypes; ** $P = 0.009$ significantly different from combined PTK2 rs7460 AA + AT genotypes.

